Press Releases

Date	Title	View
01/24/22	Summary Toggle Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)	PDF Version
01/10/22	Summary Toggle Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout	PDF Version
01/06/22	Summary Toggle Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability	PDF Version
12/23/21	Summary Toggle Horizon Therapeutics plc to Participate in Upcoming Investor Conferences	PDF Version
12/16/21	Summary Toggle Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases	PDF Version
12/02/21	Summary Toggle Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater	PDF Version
12/02/21	Summary Toggle Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List	PDF Version
12/01/21	Summary Toggle Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education	PDF Version
11/22/21	Summary Toggle New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)	PDF Version
11/15/21	Summary Toggle Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative	PDF Version